White matter and its relationship with cognition in subjective cognitive decline
Abstract
Subjective cognitive decline (SCD) is the earliest stage on the continuum toward Alzheimer's disease. This study examined (1) differences in white matter integrity between individuals with SCD and healthy control subjects and (2) how white matter integrity related to memory and executive function.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 21, 2018
- Source ID
- 10.1016/j.dadm.2018.10.008
Entities
People
- Ashleigh F. Parker
- Colette M. Smart
- Jodie R. Gawryluk
- Lisa Ohlhauser
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- University of Southern California
- University of Victoria